Results 121 to 130 of about 49,721 (234)

Comparison of Efficacy Between Nab-Paclitaxel or Docetaxel Combined with Carboplatin as Neoadjuvant Therapy for HER2-Positive Breast Cancer

Zhongliu Fangzhi Yanjiu
ObjectiveTo compare the efficacy of trastuzumab plus pertuzumab (HP) combined with either nab-paclitaxel plus carboplatin or docetaxel plus carboplatin as neoadjuvant therapy for HER2-positive breast cancer in real-world clinical practice ...
Xin HAO, Chongzhu HU, Ruixue YUE, Tianpei MIAO, Zhong LI   +4 more
doaj   +1 more source

Breast Skin Lesions in a 79‐Year‐Old Woman

JEADV Clinical Practice, EarlyView.
Javier Lorenz‐Dolz, Fátima Mayo‐Martínez, Andrea Díez Santandreu, Onofre Sanmartín Jiménez, Ruggero Moro   +4 more
wiley   +1 more source

Extracellular vesicles in pharmacology: Innovations in drug delivery and therapeutic applications in cancer

British Journal of Pharmacology, EarlyView.
Extracellular vesicles (EVs) are a diverse population of membrane nanoparticles secreted by nearly all cell types, playing a key role in intercellular communication by transferring bioactive macromolecular cargo. In cancer, EVs shape both the local tumour microenvironment and distant premetastatic niches.
Evangelia Pantazaka, Georgios Sivvas, Evangelia Papadimitriou, Constantinos M. Mikelis   +3 more
wiley   +1 more source

Efficacy and safety of albumin-bound paclitaxel combined with simvastatin in the second-line treatment of small cell lung cancer: a phase II randomized controlled trial

BMC Medicine
Background Small-cell lung cancer (SCLC) responds to first-line therapy, but most patients rapidly develop resistance. This study aimed to investigate the efficacy and safety of nab-paclitaxel combined with simvastatin as second-line treatment for SCLC ...
Maoying Guan, Wencheng Zhao, Wengang Zhang, Xuyang Chen, Runze Huang, Xinyue Liu, Yujie Li, Hao Wang, Lishu Zhao, Kandi Xu, Li Ye, Zhimin Chen, Yujin Liu, Qianqian Zhang, Hongbin Ji, Yayi He   +15 more
doaj   +1 more source

nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy

, 2017
Michael Thomas,1,2 David R Spigel,3 Robert M Jotte,4 Michael McCleod,5 Mark A Socinski,6 Ray D Page,7 Laurent Gressot,8 Jeanna Knoble,9 Oscar Juan,10 Daniel Morgensztern,11 Dolores Isla,12 Edward S Kim,13 Howard West,14 Amy Ko,15 Teng Jin Ong,15 ...
Socinski MA, Juan O, Ong TJ, Morgensztern D, Ko A, Spigel DR, Kim ES, Trunova N, West H, Gridelli C, McCleod M, Page RD, Thomas M, Jotte RM, Gressot L, Isla D, Knoble J   +16 more
core  

Pleiotropic Roles of FBXO11 in Tumorigenesis: Implications for Targeted Therapy

Cancer Science, EarlyView.
This complex comprises of scaffold CUL1, SKP1, RBX1 and FBXO11 receptor. The substrate is phosphorylated by specific kinase enzyme and recognized by the substrate recognition domain. FBXO11 targets numerous substrates for ubiquitination and degradation, FBXO11 substrates mainly include Snail, ZEB1, p53, BCL6, CDT2, CIITA, Cdc25a, hnRNPA2B1, SAMD1 and ...
Yuqi Zhang, Changyi Fan, Shiheng Chen, Tianyue Lu, Yuanyuan Li, Feng Du, Shanshan Wang   +6 more
wiley   +1 more source

Daraxonrasib and Beyond: Pan‐RAS Inhibition, Resistance, and Next‐Generation Strategies

Cancer Science, EarlyView.
ABSTRACT RAS proteins have long been considered difficult therapeutic targets, but allele‐selective inhibitors established the clinical tractability of mutant RAS. Daraxonrasib (RMC‐6236), an oral pan‐RAS inhibitor, has now extended this concept by targeting multiple mutant and wild‐type RAS proteins.
Ryo Honda
wiley   +1 more source

Impact of nab-paclitaxel-based second-line chemotherapy on the outcomes of pancreatic cancer.

, 2017
483 Background: Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with no standard second line chemotherapies. We conducted a retrospective study with the primary aim to examine the effect of second line chemotherapy with nab-paclitaxel ...
Bert H. O'Neil, Safi Shahda, Neelakanta Dadi, Amikar Sehdev   +3 more
core   +1 more source

Genotype‐Informed Whole‐Animal Kinome Screening Reveals Shared Kinase Vulnerabilities Across Driver Contexts in PDAC

Cancer Science, EarlyView.
Overview of experimental workflow and key findings. Clinically prevalent 2‐hit and 3‐hit PDAC genotypes were first modeled in Drosophila to enable kinome‐wide genetic screening. Candidate therapeutic targets were prioritized using human tumor expression data and pathway enrichment analyses.
Han Hai, Takako Ooshio, Hui Jiang, Taku Kimura, Yusuke Satoh, Soichiro Hata, Taiga Hirata, Jiayi Liu, Tongwei Liu, Ryodai Yamamura, Masahiro Sonoshita   +10 more
wiley   +1 more source

Table_1_nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLC.docx

, 2018
The phase 4 ABOUND.70+ trial assessed the safety and efficacy of nab-paclitaxel/carboplatin continuously or with a 1-week break between cycles in elderly patients with advanced non-small cell lung cancer (NSCLC).
Matei P. Socoteanu (5546894), Teng J. Ong (5546897), Manuel Modiano (5546885), Kartik Konduri (5546879), Eric C. Anderson (3073926), Jonathan W. Goldman (5546906), on behalf of the ABOUND.70+ Investigators (5546903), Daniel E. Haggstrom (5546888), Edward S. Kim (2183847), Corey J. Langer (5546882), Robert M. Jotte (5546891), Tymara Berry (5546843), Jared Weiss (5546900), Christopher Dakhil (5546876), Alexandra Sanford (5546849), Katayoun Amiri (5546870), David A. Smith (2577271)   +16 more
core   +1 more source